Article
Oncology
Kyung Su Kim, Hong-Gyun Wu
Summary: Charged-particle therapy, such as proton beam therapy and carbon-ion radiotherapy, has physical and biological advantages over conventional photon radiotherapy, particularly in treating pediatric cancer and radioresistant tumors. However, high setup costs and lack of clinical evidence hinder widespread adoption. Clinical studies are being conducted to increase the number of patients who can benefit from charged-particle therapy despite its high cost.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Jong Min Park, Jung-In Kim, Hong-Gyun Wu
Summary: Charted-particle therapy offers localized doses to tumors and minimizes doses to normal tissues. Carbon-ion radiotherapy has become mainstream in cancer treatment using heavy ions, with continuous technological advancements and ongoing global research.
CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Wanrong Luo, Yasser F. Ali, Chong Liu, Yuchen Wang, Caorui Liu, Xiaoni Jin, Guangming Zhou, Ning-Ang Liu
Summary: Hadron therapy using protons and carbon ions is gaining interest as a potential alternative to traditional photon radiotherapy. The precise dose distribution of charged particles allows for better tumor control and reduced damage to healthy tissues. The high-linear energy transfer characteristics of heavy ions offer biological advantages, making them a promising approach for treating breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Hanguang Ruan, Masahiko Okamoto, Tatsuya Ohno, Yang Li, Yuan Zhou
Summary: Breast cancer is the most common malignant tumor in women, and radiotherapy is a common treatment. Although breast cancer radiotherapy technology has improved, complications should not be overlooked. Common complications include coronary toxicity, radiation pneumonia, and the risk of second primary cancer. Proton and carbon-ion radiotherapy have attracted interest as potential alternatives to conventional photon radiotherapy. This article summarizes clinical research on proton and carbon-ion radiotherapy for breast cancer treatment.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Arnold Pompos, Robert L. Foote, Albert C. Koong, Quynh Thu Le, Radhe Mohan, Harald Paganetti, Hak Choy
Summary: This review advocates for the establishment of a limited number of heavy ion cancer research and treatment facilities in the United States. Based on research in physics, biology, and clinical trials, heavy ions have the potential to significantly enhance the therapeutic ratio for various types of cancer compared to conventional X-ray and proton radiotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yuichi Hiroshima, Hitoshi Ishikawa, Yuma Iwai, Masaru Wakatsuki, Takanobu Utsumi, Hiroyoshi Suzuki, Koichiro Akakura, Masaoki Harada, Hideyuki Sakurai, Tomohiko Ichikawa, Hiroshi Tsuji
Summary: As the population ages, the choice of treatment options for elderly prostate cancer patients with poor general condition is becoming more difficult. This retrospective study evaluated the clinical outcomes of carbon-ion radiotherapy for elderly high-risk prostate cancer patients and found that it may be a safe and effective treatment.
Review
Oncology
Meixuan Li, Xiuxia Li, Liang Yao, Xue Han, Wenlong Yan, Yujun Liu, Yiwen Fu, Yakun Wang, Min Huang, Qiuning Zhang, Xiaohu Wang, Kehu Yang
Summary: Both CIRT and PBT show favorable efficacy and safety for prostate cancer, with potential benefits compared to photon radiotherapy. However, the current evidence is of low certainty and more high-quality studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Wai Tong Ng, Barton But, Charlene H. L. Wong, Cheuk-Wai Choi, Melvin L. K. Chua, Pierre Blanchard, Anne W. M. Lee
Summary: This systematic review and meta-analysis demonstrated that particle beam therapy has great potential in treating nasopharyngeal cancer, yielding excellent survival outcomes with low toxicity. However, further investigations are needed to assess the long-term outcomes and cost-effectiveness of this newer form of radiotherapy.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2022)
Article
Oncology
Verity Ahern, Sebastian Adeberg, Piero Fossati, Richard Garrett, Bradford Hoppe, Anita Mahajan, Ester Orlandi, Roberto Orecchia, Dale Prokopovich, Jan Seuntjens, David Thwaites, Daniel Trifiletti, Richard Tsang, Hiroshi Tsuji
Summary: This study aims to establish the treatment indications and potential patient numbers for carbon ion radiation therapy (CIRT) at a proposed national carbon ion (and proton) therapy facility in New South Wales, Australia. An expert panel, including representatives from operational and proposed international carbon ion facilities, as well as local stakeholders, met virtually to discuss the available evidence and experience. The study concluded that CIRT can be justified in Australia for certain tumor types, including adenoid cystic carcinomas, mucosal melanomas, hepatocellular cancer, liver metastases, base of skull meningiomas, chordomas, and chondrosarcomas. Approximately 1400 Australian patients annually meet the consensus-derived indications.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Masahiko Okamoto, Shintaro Shiba, Daijiro Kobayashi, Yuhei Miyasaka, Shohei Okazaki, Kei Shibuya, Tatsuya Ohno
Summary: This study evaluated the clinical impact of carbon-ion radiotherapy (CIRT) with concurrent chemotherapy for locally advanced unresectable pancreatic cancer (URPC). The results showed that CIRT has survival benefits for URPC even in the multiagent chemotherapy era.
Review
Health Care Sciences & Services
Yoshitaka Matsumoto, Nobuyoshi Fukumitsu, Hitoshi Ishikawa, Kei Nakai, Hideyuki Sakurai
Summary: This paper discusses the role of particle therapy in multidisciplinary treatment, with a focus on proton beam therapy, carbon-ion beam therapy, and boron neutron capture therapy. It emphasizes the combination of different drug therapies and the importance of selective drug delivery research for enhancing treatment effects. The review provides insights into both clinical and basic aspects of particle beam therapy for future expansion.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Yanliang Chen, Hongtao Luo, Ruifeng Liu, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Zhiqiang Liu, Shilong Sun, Qiuning Zhang, Xiaohu Wang
Summary: This study aimed to evaluate the efficacy and safety of particle therapy in inoperable locally advanced non-small cell lung cancer (LA-NSCLC). A systematic search was conducted, and 19 eligible studies with a total sample size of 851 patients were included. The results demonstrated that particle therapy had promising efficacy and acceptable toxicity in LA-NSCLC patients.
RADIATION ONCOLOGY
(2023)
Article
Oncology
Katharina Seidensaal, Matthias Dostal, Jakob Liermann, Sebastian Adeberg, Fabian Weykamp, Maximillian P. Schmid, Christian Freudlsperger, Juergen Hoffmann, Ivar Hompland, Klaus Herfarth, Juergen Debus, Semi B. Harrabi
Summary: This study reported the survival of craniofacial osteosarcoma patients treated with particle radiotherapy. CIBRT showed promising results, and age, diagnosis type, and tumor residue were identified as factors associated with improved survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Ester Orlandi, Amelia Barcellini, Barbara Vischioni, Maria Rosaria Fiore, Viviana Vitolo, Alberto Iannalfi, Maria Bonora, Agnieszka Chalaszczyk, Rossana Ingargiola, Giulia Riva, Sara Ronchi, Francesca Valvo, Piero Fossati, Mario Ciocca, Alfredo Mirandola, Silvia Molinelli, Andrea Pella, Guido Baroni, Marco Giuseppe Pullia, Angelica Facoetti, Roberto Orecchia, Lisa Licitra, Gianluca Vago, Sandro Rossi
Summary: Carbon ion radiotherapy has advantages in rare, radioresistant, and difficult-to-treat tumors. CNAO has made significant contributions to the field and continuously improved its clinical, technical, and dosimetric skills.
Article
Oncology
Masashi Yagi, Yutaka Takahashi, Kazumasa Minami, Taeko Matsuura, Jin-Min Nam, Yasuhito Onodera, Takashi Akagi, Takuya Maeda, Tomoaki Okimoto, Hiroki Shirato, Kazuhiko Ogawa
Summary: The study revealed significant heterogeneity in RBE values of proton and carbon-ion beams across various sarcomas and normal-tissue-derived cell lines, suggesting potential benefits of proton beam therapy for certain tumors and the need for dose adjustments based on RBE differences in carbon-ion therapy.
Article
Oncology
Goro Kasuya, Hiroshi Tsuji, Takuma Nomiya, Hirokazu Makishima, Yasuo Haruyama, Gen Kobashi, Daniel K. Ebner, Kazuhiko Hayashi, Tokuhiko Omatsu, Riwa Kishimoto, Shigeo Yasuda, Tatsuo Igarashi, Mototsugu Oya, Koichiro Akakura, Hiroyoshi Suzuki, Tomohiko Ichikawa, Jun Shimazaki, Tadashi Kamada
Article
Public, Environmental & Occupational Health
Shiho Kino, Soong-nang Jang, Shuko Takahashi, Daniel K. Ebner, Ichiro Kawachi
SOCIAL SCIENCE & MEDICINE
(2020)
Review
Critical Care Medicine
Euma Ishii, Daniel K. Ebner, Satoshi Kimura, Louis Agha-Mir-Salim, Ryo Uchimido, Leo A. Celi
JOURNAL OF INTENSIVE CARE
(2020)
Review
Oncology
Timothy D. Malouff, Danushka S. Seneviratne, Daniel K. Ebner, William C. Stross, Mark R. Waddle, Daniel M. Trifiletti, Sunil Krishnan
Summary: Boron neutron capture therapy (BNCT) is an emerging treatment modality that utilizes boron-10 to target tumors and has shown promising results in various cancer types in clinical studies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Daniel K. Ebner, Steven J. Frank, Taku Inaniwa, Shigeru Yamada, Toshiyuki Shirai
Summary: The research on high linear energy transfer (LET) radiotherapy has been ongoing for over half a century, with a focus now on carbon-ion beams due to their promising suitability in treating hypoxic and/or radioresistant cancers. Challenges remain in terms of technical development and limitations imposed by the physical properties of the beams.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Liqiu Ma, Yoshimitsu Sakamoto, Ken Ando, Hidetoshi Fujita, Akihisa Takahashi, Tsuguhide Takeshima, Hiromi Otsuka, Daniel K. Ebner, Kazuhiro Kakimi, Takashi Imai, Takashi Shimokawa
Summary: The study aims to clarify the mechanisms of metastasis suppression by carbon-ion radiotherapy combined with immature dendritic cell immunotherapy (CiDC). CiDC was found to effectively suppress lung metastasis in mouse models, and the genetic background of the host may have an impact on the efficacy of combination therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Letter
Medical Informatics
Christopher V. Cosgriff, Daniel K. Ebner, Leo Anthony Celi
LANCET DIGITAL HEALTH
(2020)
Article
Oncology
Shigeo Yasuda, Hirotoshi Kato, Hiroshi Imada, Yuka Isozaki, Goro Kasuya, Hirokazu Makishima, Hiroshi Tsuji, Daniel K. Ebner, Shigeru Yamada, Tadashi Kamada, Hirohiko Tsujii, Naoya Kato, Masaru Miyazaki
ADVANCES IN RADIATION ONCOLOGY
(2020)
Review
Oncology
Yuka Isozaki, Hirotoshi Takiyama, Tapesh Bhattacharyya, Daniel Ebner, Goro Kasuya, Hirokazu Makishima, Hiroshi Tsuji, Tadashi Kamada, Shigeru Yamada
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2020)
Article
Oncology
Hiroaki Ikawa, Masashi Koto, Daniel K. Ebner, Kazuhiko Hayashi, Ryo Takagi, Morio Tonogi, Takeshi Nomura, Hiroshi Tsuji, Tadashi Kamada
ADVANCES IN RADIATION ONCOLOGY
(2019)
Article
Oncology
Alexander Helm, Daniel K. Ebner, Walter Tinganelli, Palma Simoniello, Alessandra Bisio, Valentina Marchesano, Marco Durante, Shigeru Yamada, Takashi Shimokawa
INTERNATIONAL JOURNAL OF PARTICLE THERAPY
(2018)